TRCT
IPSC icon

Tower Research Capital (TRC)’s Century Therapeutics IPSC Stock Holding History

Tower Research Capital (TRC)’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6K Sell
12,483
-20,504
-62% -$46.8K ﹤0.01% 3163
2026
Q1 		$74.6K Buy
+32,987
New +$69.4K ﹤0.01% 2414
2025
Q4 		– Sell
-13,116
Closed -$6.53K – 5373
2025
Q3 		$6.53K Sell
13,116
-9,246
-41% -$4.99K ﹤0.01% 4155
2025
Q2 		$12.5K Buy
22,362
+4,854
+28% +$2.6K ﹤0.01% 3884
2025
Q1 		$8.33K Buy
17,508
+7,699
+78% +$5.78K ﹤0.01% 3900
2024
Q4 		$9.91K Buy
9,809
+2,709
+38% +$3.69K ﹤0.01% 3863
2024
Q3 		$12.1K Sell
7,100
-9,932
-58% -$19.5K ﹤0.01% 3615
2024
Q2 		$43.4K Buy
17,032
+12,676
+291% +$40.1K ﹤0.01% 3209
2024
Q1 		$18.2K Buy
4,356
+406
+10% +$1.72K ﹤0.01% 3080
2023
Q4 		$13.1K Sell
3,950
-23,901
-86% -$43.5K ﹤0.01% 3982
2023
Q3 		$55.7K Buy
27,851
+24,879
+837% +$66.2K ﹤0.01% 2454
2023
Q2 		$9.39K Buy
2,972
+760
+34% +$2.45K ﹤0.01% 4291
2023
Q1 		$8K Sell
2,212
-6,740
-75% -$29.6K ﹤0.01% 4636
2022
Q4 		$46K Buy
8,952
+4,795
+115% +$45.3K ﹤0.01% 2409
2022
Q3 		$41K Buy
4,157
+904
+28% +$9.52K ﹤0.01% 3336
2022
Q2 		$27K Buy
3,253
+2,459
+310% +$24.1K ﹤0.01% 3472
2022
Q1 		$10K Sell
794
-2,271
-74% -$30.1K ﹤0.01% 4316
2021
Q4 		$49K Buy
3,065
+2,468
+413% +$46.4K ﹤0.01% 2771
2021
Q3 		$15K Buy
+597
New +$16.2K ﹤0.01% 3979

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Tower Research Capital (TRC)'s IPSC Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Century Therapeutics (IPSC) stake by 62% in Q2 2026, selling an estimated $46.8K and leaving 12,483 shares worth $30.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3163.

Tower Research Capital (TRC) first reported a position in IPSC in Q3 2021 and has held it in 19 quarters since. The position peaked at $74.6K in Q1 2026. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Tower Research Capital (TRC) held 12,483 shares of Century Therapeutics worth $30.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 20,504 Century Therapeutics shares in Q2 2026, an estimated $46.8K.
  • Century Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3163 holding.
  • Tower Research Capital (TRC) first reported a position in Century Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Century Therapeutics position peaked at $74.6K in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.